Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Svetlana, Trestman"'
Autor:
Iuliana Vaxman, Itai Zamir, Inbar Cohen, Gil Fridberg, Tamir Shragai, Svetlana Trestman, Tomer Ziv, Efrat Luttwak, Ronit Shmuel, Natan Melamed, Shai Levi, Irit Avivi, Pia Raanani, Angela Dispenzieri, Morie Gertz, Yael Cohen
Publikováno v:
HemaSphere, Vol 7, p e949198b (2023)
Externí odkaz:
https://doaj.org/article/411821568d2a40c2b9c49d370ef3c57a
Autor:
Gil Fridberg, Tamir Shragai, Natan Melamed, Svetlana Trestman, Iuliana Vaxman, Irit Avivi, Yael Cohen
Publikováno v:
HemaSphere, Vol 7, p e5068793 (2023)
Externí odkaz:
https://doaj.org/article/3036596ba2d543c5bad9d0331f4207c3
Autor:
Efrat Markus, Svetlana Trestman, Yael Cohen, Yoel Angel, Yael Sofer, Moshe Mittelman, Irit Avivi, Naftali Stern, Elena Izkhakov
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background The prevalences of diabetes mellitus and hypertension, both of which are components of metabolic syndrome, are known to be increased among patients with multiple myeloma (MM), but remain undetermined among patients with smoldering
Externí odkaz:
https://doaj.org/article/dd792a44e0404f0192994fbcc285cf2f
Autor:
Roy Vitkon, Dan Netanely, Shai Levi, Tomer Ziv-Baran, Ronit Ben-Yzak, Ben-Zion Katz, Noam Benyamini, Svetlana Trestman, Moshe Mittelman, Yael Cohen, Irit Avivi
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Background: Daratumumab (Dara) is generally well tolerated, but is associated with increased risk of infection. Methods: We investigated hypogammaglobinemia occurrence in different Dara-based regimens. Multiple myeloma (MM) patients were treated with
Externí odkaz:
https://doaj.org/article/dd8de47cc8b34c739af4fc1aec55c49c
Autor:
Tamir, Shragai, Hila, Magen, Noa, Lavi, Moshe, Gatt, Svetlana, Trestman, Miri, Zektser, Chezi, Ganzel, Osnat, Jarchowsky, Tamar, Berger, Tamar, Tadmor, Merav, Leiba, Katrin, Hertzog-Tzarfaty, Netanel, Horowitz, Michael, Shapira, David, Varssano, Yoav, Berger, Shahar, Frenkel, Mark, Krauthammer, Irit, Avivi, Efrat, Luttwak, Yael C, Cohen
Publikováno v:
British Journal of Haematology. 200:45-53
Belantamab mafodotin, an immuno-conjugate targeting B-cell maturation antigen, showed single-agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real-world da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9cac5564db9f37bf2f2beb017c50180
https://doi.org/10.1111/bjh.18479
https://doi.org/10.1111/bjh.18479
Autor:
Chezi Ganzel, Svetlana Trestman, Shai Levi, Moshe E. Gatt, Noa Lavi, Iuliana Vaxman, Ory Rouvio, Hila Magen, Eyal Lebel, Netanel A. Horowitz, Merav Leiba, Tamar Tadmor, Katrin Herzog Tzarfati, Celia Surio, Shay Yeganeh, Nagib Dally, Irit Avivi, Yael C. Cohen
Publikováno v:
Leukemialymphoma.
Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia. In this retrospective multicenter study, 68 SP patients were included. Compared to solitary extramedullary plasmacytoma (SEP), patients with solitary bone plasmacytoma (SBP) were younger (57
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdec4d63020a5d4345c2041897eec3f5
https://pubmed.ncbi.nlm.nih.gov/36075048
https://pubmed.ncbi.nlm.nih.gov/36075048
Autor:
Svetlana Trestman, Irit Avivi, Moshe Mittelman, Tamir Shragai, Chava Perry, Yaara Tabib, Yair Herishanu, Tali Bar Lev, Yael C Cohen, Noa Lowenton-Spier, Noam Benyamini, Roi Balaban, Miguel Morales, Gabi Sheffer, Anat Aharon, Efrat Luttwak, Mor Zavaro
Publikováno v:
British Journal of Haematology
Summary Multiple myeloma (MM) patients are at excess risk for clinically significant COVID19 infection. BNT162b2 mRNA COVID19 (BNT162b2) vaccine provides effective protection against COVID19 for the general population, yet its effect in MM patients m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c451233c0d41c763908d9024d6f6a5
https://doi.org/10.1111/bjh.17608
https://doi.org/10.1111/bjh.17608
Autor:
Yotam Bronstein, Roi Gat, Shai Levi, Yael C. Cohen, Efrat Luttwak, Noam Benyamini, Tamir Shragai, Roy Vitkon, Miriam Neaman, Nili Eilaty, Mor Levi, Svetlana Trestman, Chava Perry, Yair Herishanu, Irit Avivi
Publikováno v:
Cancer cell. 40(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c1805b5052a7dadec80c51361bbeed7
https://pubmed.ncbi.nlm.nih.gov/35477028
https://pubmed.ncbi.nlm.nih.gov/35477028
Autor:
Naftali Stern, Irit Avivi, Yael Sofer, Efrat Markus, Yael C Cohen, Moshe Mittelman, Svetlana Trestman, Elena Izkhakov, Yoel Angel
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Cancer
BMC Cancer
Background The prevalences of diabetes mellitus and hypertension, both of which are components of metabolic syndrome, are known to be increased among patients with multiple myeloma (MM), but remain undetermined among patients with smoldering MM (SMM)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ada41dcb99e9747ab35c9f1ae97f37a
http://link.springer.com/article/10.1186/s12885-020-06976-1
http://link.springer.com/article/10.1186/s12885-020-06976-1
Autor:
Dan Netanely, Ben-Zion Katz, Ronit Ben-Yzak, Irit Avivi, Shai Levi, Roy Vitkon, Svetlana Trestman, Moshe Mittelman, Yael C Cohen, Tomer Ziv-Baran, Noam Benyamini
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Therapeutic Advances in Hematology
Therapeutic Advances in Hematology
Background: Daratumumab (Dara) is generally well tolerated, but is associated with increased risk of infection. Methods: We investigated hypogammaglobinemia occurrence in different Dara-based regimens. Multiple myeloma (MM) patients were treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15550bca08e1508ae2207665a2577170
https://doaj.org/article/dd8de47cc8b34c739af4fc1aec55c49c
https://doaj.org/article/dd8de47cc8b34c739af4fc1aec55c49c